Trial Profile
Randomized Phase II/III Study of Nivolumab Plus Ipilimumab Plus Sargramostim Versus Nivolumab Plus Ipilimumab in Patients With Unresectable Stage III or Stage IV Melanoma
Status:
Recruiting
Phase of Trial:
Phase II/III
Latest Information Update: 24 Apr 2024
Price :
$35
*
At a glance
- Drugs Ipilimumab (Primary) ; Nivolumab (Primary) ; Sargramostim (Primary)
- Indications Malignant melanoma
- Focus Therapeutic Use
- 18 Apr 2024 According to a Partner Therapeutics media release, this trial heads to last stages of enrollment.
- 23 Sep 2023 Planned End Date changed from 6 Aug 2023 to 30 Jun 2033.
- 23 Sep 2023 Planned primary completion date changed from 6 Aug 2023 to 30 Jun 2033.